|
|
|
|
Vol. 61, Issue 2, 436-445, February 2002
Departments of Psychiatry (K.Y.L., H.Z., L.Z.) and Neurology (L.W.E.), University of Michigan, Ann Arbor, Michigan; and Ann Arbor Veterans Affairs Medical Center, Ann Arbor, Michigan (K.Y.L., L.W.E., J.O.S.)
| |
Abstract |
|---|
|
|
|---|
Several previous human postmortem experiments have detected an increase
in striatal [3H]WIN 35428 binding to the dopamine
transporter (DAT) in chronic cocaine users. However, animal experiments
have found considerable variability in DAT radioligand binding levels
in brain after cocaine administration, perhaps caused by length and
dose of treatment and type of radioligand used. The present experiments
tested the hypothesis that [3H]WIN 35428 binding and
[3H]dopamine uptake would be increased by exposure to
cocaine through alterations in DAT cellular trafficking, rather than
increased protein synthesis. Experiments were conducted in stably
hDAT-transfected N2A cells and assessed the dose response and time
course of cocaine effects on [3H]WIN 35428 binding to the
DAT, [3H]dopamine uptake, measures of DAT protein and
mRNA, as well as DAT subcellular location. Cocaine doses of
10
6 M caused statistically significant increases in
[3H]WIN 35428 binding and [3H]dopamine
uptake after 12 and 3 h, respectively. Despite these increases in
DAT function, there was no change in DAT total protein or mRNA.
Immunofluorescence and biotinylation experiments indicated that cocaine
treatment induced increases in plasma membrane DAT immunoreactivity and
intracellular decreases. The present model system may further our
understanding of regulatory alterations in DAT radioligand binding and
function caused by cocaine exposure.
| |
Introduction |
|---|
|
|
|---|
Clinical
studies indicate that human cocaine users dying during exposure to
cocaine have increased striatal [3H]WIN 35428 binding to the dopamine transporter (DAT; Little et al., 1993
, 1998
,
1999
; Staley et al., 1994
), accompanied by up-regulation of dopamine
uptake (Mash et al., 1997
). Such functional alterations could be
important, perhaps contributing to cocaine-induced binging, withdrawal
symptoms, or craving. Beyond drug self-administration, dopamine neurons
play a role in other rewarding phenomena, including sex (Everitt, 1990
)
and eating (Phillips et al., 1993
), suggesting that regulatory
alterations in DAT function could have interesting implications for
understanding the dynamics of a number of motivational and appetitive
processes. Recent experiments in cell culture have determined that
phosphorylative treatments (Pristupa et al., 1998
; Daniels et al.,
1999
; Melikian and Buckley, 1999
) or exposure to the stimulant
d-amphetamine (Saunders et al., 2000
) dynamically regulate
DAT function by changing DAT cellular localization, perhaps invoking
mechanisms that might be related to those activated by cocaine.
Understanding the mechanisms involved in DAT binding site changes is important because 1) binding site alterations are the primary alterations documented in postmortem brain from cocaine users; 2) DAT inhibitors/ligands are being developed extensively as both therapeutic and imaging agents for both the DAT as well as dopamine neurons; and 3) DAT regulation may provide broader insights into the pharmacological effects of drugs on transporter binding sites. In addition to our need to uncover cocaine's neurochemical effects that provoke symptoms associated with its dependence, it is possible that new therapeutic or imaging agents (many of which are often DAT uptake inhibitors) might themselves induce adaptations in DAT function, as well as alter cocaine's effect on dopamine uptake. Also, potentially, DAT inhibitor binding sites could be altered through some mechanism that is independent of changes in DAT concentration or function.
Human experiments examining the effects of cocaine on DAT regulation
(Hurd and Herkenham, 1993
; Hitri et al., 1995
; Wilson et al., 1996
), as
well as a number of animal experiments (Kula and Baldessarini, 1991
;
Benmansour et al., 1992
; Alburges et al., 1993
; Koff et al., 1994
;
Wilson et al., 1994
; Hitri et al., 1996
; Pilotte et al., 1996
;
Letchworth et al., 2000
), have found variability in DAT binding levels
after cocaine administration, for reasons that remain unclear. Animal
experiments have varied a great deal in the dose, route, and length of
cocaine administered, the withdrawal time after cocaine exposure, as
well as the radioligand used to examine binding changes, and any of
these and other factors may have contributed to the varied results.
Although the literature is complex, relatively higher cocaine doses and
longer treatment courses have seemed necessary to induce increases in
DAT binding in animals (Alburges et al., 1993
; Koff et al., 1994
;
Wilson et al., 1994
; Hitri et al., 1996
; Letchworth et al., 2000
).
Also, because some radioligands (such as
[3H]WIN 35428) seem more likely to demonstrate
cocaine-induced increases than others (such as
[3H]mazindol), this suggest that changes in DAT
compartmentalization, rather than total synthesis, may be involved.
Although cocaine interferes with d-amphetamine-induced DAT
internalization (Saunders et al., 2000
), no previous experiments have
determined if there are effects of cocaine alone on DAT trafficking.
Previously, the pharmacological resemblance of
[3H]WIN 35428 binding to DAT expressed in a
cell culture system employing neuro2A cells (N2A, derived from mouse
neuroblastoma) to that in human brain, has been documented (Zhang et
al., 1998
). Preliminary data also indicated that alterations in
[3H]WIN 35428 binding occurred after a 24-h
exposure to cocaine, a period of time longer than that reported for
d-amphetamine effects in another model system (after 1 h, there were substantial declines in dopamine uptake; Saunders et al.,
2000
). The present experiments were designed to determine the dose
response and time dependence of cocaine effects on DAT binding sites,
the degree to which binding site changes paralleled dopamine uptake
changes, and the mechanism involved. Our initial hypothesis was that
[3H]WIN 35428 binding and
[3H]dopamine uptake would be increased by
exposure to cocaine through alterations in DAT cellular trafficking,
rather than increased protein synthesis. To test this theory,
experiments assessed total DAT protein, DAT mRNA, and the subcellular
localization of DAT after cocaine treatment. Follow-up experiments
searched for a possible role of dopamine in modulating the effects of
cocaine on the DAT.
| |
Materials and Methods |
|---|
|
|
|---|
hDAT-Transfected Cell Cultures.
As described previously
(Zhang et al., 1998
), N2A cells were obtained from American Type
Culture Collection (Manassas, VA). Briefly, the cells were grown in
Opti-MEM I (Invitrogen, Carlsbad, CA)/10% FBS/1%
penicillin-streptomycin in 75-cm2 flasks. After
reaching confluence (about 3 days of growth), the cells were collected
by trypsinization and transfected with hDAT-cDNA [provided by Zdenek
Pristupa (University of Toronto, Toronto, ON, Canada), cloned into the
pcDNA3 plasmid]. Transfection was accomplished by electroporation
employing a BTX Electroporation System 600 (Biotechnologies and
Experimental Research, Inc., San Diego, CA). After selection with
Geneticin over several weeks, cells were grown to confluence and then
distributed in 24 well plates and allowed to reattach for 24 h
before all assays described below. After cocaine or vehicle treatment
as described below, cells were thoroughly washed to remove residual
cocaine before assay.
Radioligand Binding Assays.
The methods used to assay
[3H]WIN 35428 (also known as
[3H]CFT) binding have been described previously
(Little et al., 1993
, 1999
). Briefly, [3H]WIN
35428 assays used a 0.32 M sucrose and 10 mM
Na2HPO4 buffer at pH 7.4 (except one series of [3H]WIN 35428 experiments
that compared 50 mM Tris/120 mM NaCl buffer with sucrose/phosphate
buffer). Saturation experiments were performed by homologous
displacement. A 3 nM radiolabeled concentration of
[3H]WIN 35428 (specific activity, 80 Ci/mmol;
PerkinElmer, Boston, MA) was used at the equilibrium conditions
determined previously (1 h at 2°C), in conjunction with eight WIN
35428 concentrations, from 10
10 to
10
5 M. Incubations were performed with intact
cells, which were terminally washed with buffer for 2 to 3 min. Similar
outcomes were obtained when cells were either mechanically scraped and
filtered over Whatman GF/B glass fiber filters presoaked in 0.01%
polyethylenimine or when solubilized in SDS and the product counted.
Nonspecific binding was defined with 30 µM (
)-cocaine. Specific
binding with [3H]WIN 35428 averaged 80 to 85%
as a fraction of total binding. The cells in one or two wells of each
plate were dissolved with 1 ml of 1 N NaOH, and the concentration of
protein was determined (Bio-Rad, Hercules, CA). Approximately 0.2 mg of
protein was obtained from one well. It should be noted that because
only eight concentrations of radioligand were used in the present
series of saturation experiments, these conditions were not optimal for
the detection of two binding sites. The decision to use only eight
concentrations was based on the consistent preference for a one-site
model in previous [3H]WIN 35428 binding assays
that used 16 radioligand concentrations and the same buffer conditions
(Little et al., 1999
). Both one-site (Wilson et al., 1996a
; Xu and
Reith, 1997
) and two-site models (Madras et al., 1989
; Staley et al.,
1994
) have been reported for [3H]WIN 35428. Detection of one versus two sites depends on fairly subtle differences
in assay characteristics (Coffey and Reith, 1993
; Xu and Reith, 1997
).
WIN 35428 was supplied by Dr. Ivy Carroll (Research Triangle Institute,
NC). (
)-Cocaine and dopamine were purchased from Sigma Chemicals (St.
Louis, MO).
[3H]Dopamine Uptake Assays.
[3H]Dopamine (specific activity, 35 Ci/mmol;
PerkinElmer) was added to wells to reach a final concentration of 10 nM
and total volume of 0.5 ml (Krebs phosphate buffer), followed by
incubation for 5 min (uptake linear) at 37°C on a plate shaker.
Uptake was terminated by removing assay medium immediately after
incubation using a Brandel 48-well cell harvester, followed by two
washes with 1 ml of ice-cold Krebs phosphate buffer. hDAT-N2A cells
were then dissolved in 0.8 ml of 1% SDS. The entire liquid content of
each well was transferred to a scintillation vial and assayed for
radioactivity with 5 ml of CytoScint cocktail (EcoLite; ICN Biomedicals, Costa Mesa, CA) by liquid scintillation counting in an IC
spectrometer (model LS 6500; Beckman Coulter, Fullerton,CA). Nonspecific uptake was defined with 30 µM (
)-cocaine. Protein concentrations were again determined using a commercial assay kit
(Bio-Rad).
Western Blots. Proteins were extracted, diluted in sample buffer, incubated at 100°C for 5 min, and separated by SDS-polyacrylamide gel electrophoresis (PAGE) using a 7.5% polyacrylamide solution. Proteins were then electrophoretically transferred to nitrocellulose membranes at 60 mA overnight. Blots were incubated with 5% (w/v) nonfat dry milk in TTBS buffer (0.1% Tween 20, 0.15 M NaCl, and 10 mM Tris-HCl, pH 7.4) for 1 h. Rabbit anti-hDAT carboxy-terminal polyclonal antibody (Chemicon, Inc., Temecula, CA) was diluted with 1% bovine serum albumin in TTBS buffer (1:1000), incubated with the blots for 1 h, and gently washed with TTBS buffer. Alkaline phosphatase-conjugated goat anti-rat IgG (1:5000 dilution; Jackson ImmunoResearch Laboratories, West Grove, PA) was then incubated with blots for 1 h and washed extensively with double distilled H2O. The antigen-antibody complex was detected with 5-bromo-4-O-chloro-3-indolylphosphate and nitro blue tetrazolium. All steps were performed at room temperature. The relative optical density of protein bands was quantitated using a MCID image analysis system (Microcomputer Imaging Devices, Ottawa, ON, Canada). In addition, a control experiment was performed to determine whether cocaine exposure had any effect on actin, a ubiquitous cell structural component. After quantification of DAT immunoreactivity (IR), control and cocaine treated membranes from three experiments were stripped and reprobed for actin immunoreactivity (antibody from Chemicon, Inc.), using assay conditions similar to those described above.
DAT Cell Surface Biotinylation.
Biotinylation of cell
surface-exposed hDAT was performed according to the procedures
described by Melikian et al. (1996)
. Stock solutions of
sulfo-NHS-biotine (200 mg/ml in dimethyl sulfoxide; Pierce, Rockford,
IL) were stored at
20°C before use. hDAT-N2A cells were grown in
six-well plates for 24 to 48 h until the wells were confluent.
Cocaine (1 µM) treatment was applied for 24 h before
biotinylation. After treatment, cells were washed four times with 1 ml
of ice-cold calcium- and magnesium- supplemented PBS (Ca/Mg-PBS, 138 mM
NaCl, 2.7 mM KCl, 1.5 mM
KH2PO4, 9.6 mM Na2HPO4, 1 mM
MgCl2, 0.1 mM CaCl2, pH
7.3). Sulfo-NHS-biotin solution (1 mg/ml) in Ca/Mg-PBS was incubated
with cells for 1 h at 4°C with agitation. Free sulfo-NHS-biotin
was removed by washing with ice-cold 0.1 M glycine in 1 ml Ca/Mg-PBS
twice. The reaction was further quenched by incubation with 0.1 M
glycine for 30 min and then cells were washed with Ca/Mg-PBS three
times. Biotinylated cells were solubilized in 0.5 ml of
radioimmunoprecipitation assay buffer (10 mM Tris, pH 7.4, 150 mM NaCl,
1 mM EDTA, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate),
supplemented with protease inhibitor (1 µM/ml pepstatin, 1 µM/ml
leupeptin, and 2 mM phenylmethylsulfonyl fluoride) for 1 h at room
temperature with gentle shaking. The lysis samples were centrifuged at
20,000g for 30 min at 4°C to pellet nonsolubilized
material. Supernatant was incubated with monomeric avidin beads (300 µg of protein/250 µg of beads, Pierce) for 1 h at room
temperature to separate biotinylated from nonbiotinylated protein.
Beads were washed four times with 1 ml of radioimmunoprecipitation assay buffer and the biotinylated proteins were eluted with 100 µl of
Laemmli SDS-PAGE sample buffer for 30 min at room temperature. Samples
of total cell lysates (45 µl), lysates after incubation with avidin
beads, and the bead eluate were separated by SDS-PAGE and then
quantitated, as described above under Western blots. A preliminary
control experiment assessed the extracellular specificity of the
biotinylation process, by treating whole cells with biotin, followed by
centrifugation to separate plasma membrane and cytoplasmic components
(initially 2000g for 2 min to pallet debris and undestroyed cells, followed by centrifugation of the collected supernatant at
4000g for 2 min to pellet a crude fraction showing a high
content of plasma membrane). The two fractions (2-µg pellet and
supernatant) were electrophoresed by SDS-PAGE, then stained with
streptavidin-conjugated horseradish peroxidase, which was detected by
electrochemical luminescence. Numerous biotinylated bands were present
in the plasma membrane fraction and none in the cytoplasmic fraction.
Immunofluorescence/Confocal Microscopy. hDAT-N2A cells were grown on Corning cover slips for 24 to 48 h and then appropriately treated in three ways: with vehicle, with 1 µM cocaine for 24 h, or with 5 µM PMA for 30 min. The cover slips were then fixed with 3.5% formaldehyde for 30 min and permeabilized with 0.2% saponine in phosphate-buffered saline (PBS) for 10 min, repeated once. Incubation was performed using a primary rat anti-hDAT N-terminal monoclonal antibody at 1/80 dilution for 2 h (Chemicon International Inc.). This antibody was used instead of the rabbit anti-hDAT C-terminal polyclonal because it demonstrated lower levels of diffuse background labeling. Slides were then incubated with a secondary lissamine rhodamine-conjugated goat anti-rat antibody at 1/100 dilution for 2 h (Jackson, West Grove, PA). Subcellular localization of immunofluorescently labeled hDAT was determined with an MRC-600 Confocal Imaging System (Bio-Rad). The laser beam was consistently calibrated and centered to obtain maximal brightness with minimal background. Slides were exposed to UV light for limited time periods of similar duration for each treatment group. Each cell with distinct membranal labeling in the same nondividing growth stage was uniformly included. Eight to ten digitized images were made through each cell at 0.1-µm intervals. The image of greatest horizontal extent was quantified using the MCID image analysis system, which determined the relative optical density within a cursor-determined area. Three areas were identified and quantitated for each cell: outer rim (which was always very distinctly labeled), large inclusions (which seemed to include the Golgi), and background cytoplasm. Control nontransfected N2A cells did not display labeling. Slides were quantified from three independent experiments. The results from each experiment were compared; densities obtained from individual cells across experiments were summed. A total of approximately 20 to 30 cells were quantified from each treatment group. The density of DAT immunofluorescence was quantified blind to treatment condition.
Northern Blots. Total RNA was extracted from N2A cell culture with TRIzol reagent (Invitrogen). RNA were separated by electrophoresis through agarose gels containing formaldehyde and transferred to nylon membranes (positively charged) overnight by the capillary method. After transferral, the blots were UV cross-linked. A 45-base oligonucleotide probe (AGA GCA GCA CGA TGA CCA GCA CCA GGC AGG CTG TGA GCT GCC ACC) complementary to bases 710 to 754 of the human dopamine transporter cDNA was synthesized and labeled at the 5'-end with biotin. Hybridization with oligonucleotide probe was carried out at 37°C overnight. The blots then were washed twice in 2× SSC/0.1% SDS, pH 7.0, at room temperature for 5 min each and another two times in 0.5× SSC/0.1% SDS, pH 7.0, at 37°C for 15 min each. The streptavidin/alkaline phosphatase conjugate was used for the detection of biotin-labeled nucleic acid, followed by incubation with CDP-star, an ultra-sensitive chemiluminescent substrate for alkaline phosphatase. The nylon membranes were then exposed for 2 to 7 min to chemiluminescent detection film at room temperature. The relative optical density of RNA bands was again quantitated using the MCID image analysis system.
[3H]Leucine Uptake. hDAT-N2A cells were plated in 24-well plates and treated with 1 µM cocaine or vehicle for 24 h. After treatment, cells were thoroughly washed with dopamine uptake buffer (120 mM NaCl, 4.8 mM KCl, 1.4 mM MgSO4, 16 mM Na2HPO4, 11.1 mM dextrose, 1 mm ascorbic acid, 0.03 mm pargyline, and 1.2 mM CaCl2, pH 7.4). [3H]Leucine (150 Ci/mmol; PerkinElmer) was added to wells to reach a final concentration of 1 nM and a total well volume of 0.5 ml, followed by incubation for 7 min at 37°C on a plate shaker. Varying concentrations of leucine were added (10 nM-100 µM) to each group of three wells. Nonspecific uptake was defined with either 10 mM glutamine or lysine (both found equivalent). Uptake was terminated by removing assay medium immediately after incubation, followed by two washes with buffer. Cells were dissolved in 0.55 ml of 2% SDS. The entire content of each well was transferred to a scintillation vial and assayed for radioactivity by liquid scintillation.
Inhibition of Protein Synthesis.
Rates of incorporation of
[3H]leucine were determined after treatment
with varying doses of cycloheximide, in a range of doses (0.1 to 10 µM) previously documented to curtail protein synthesis (Alirezaei et
al., 1999
). hDAT-N2A cells were grown in six-well culture plates and
treated with cycloheximide for 24 h at 37°C. Cells were then
washed twice with 1 ml of HEPES buffer (20 mM HEPES, 5.5 mM glucose,
120 mM NaCl, 5.5 mM KCl, 0.9 mM MgCl2, and 1.1 mM
CaCl2, pH 7.4) and incubated for 30 min in this
medium in the presence of 5 µM leucine.
[3H]Leucine (150 Ci/mmol; PerkinElmer) was
added to a concentration of 1 µCi/ml and incubated for an additional
30 min. Labeling was terminated by two washes in 1 ml of ice-cold
phosphate-buffered saline. Ice-cold trichloroacetic acid (1 ml; 10%
w/v) was added to each well. Cells were scraped and suspensions were
centrifuged for 10 min at 10,000g. The radioactivity of the
supernatant and pellet were counted separately by liquid scintillation.
The ratio between [3H]leucine incorporated into
proteins (pellet) and [3H]leucine taken up into
cells (supernatant) was then determined.
Serum-Free Medium versus FBS.
Because others have reported
that FBS contains serotonin and norepinephrine (Dibner and Insel, 1981
;
Cutz et al., 1985
), we assayed FBS and found it to contain dopamine and
serotonin (levels reported below). Cell expression systems commonly use
FBS because serum-containing medium strongly contributes to the rapid
and healthy growth of cells in culture. However, based on the levels discovered in FBS, and the possibility that dopamine or serotonin may
have played a role in cocaine regulation (perhaps by decreasing uptake
after intracellular transport, an effect which might then be blocked by
cocaine), two additional experiments were performed: 1) dose response
studies, using 10
8 to
10
5 M concentrations of dopamine and serotonin;
and, 2) cocaine treatment in serum-free medium (Neurobasal medium, N-2
supplement, L-glutamine; Invitrogen).
HPLC Assay (Little et al., 1996
).
FBS and Opti-MEM samples
were assayed using a mobile phase buffer of: 0.1 M citrate, 0.075 M
sodium phosphate, 0.75 mM sodium heptanesulfonate, and 17% methanol
(v/v), adjusted to pH 4.12. A C18 chromatographic column with 5-µm
microparticulate silica gel (Spherisorb ODS-2; Sigma-Aldrich
Chromatography) was used. Separations were performed isocratically at a
flow rate of 1.0 ml/min employing a pump and controller from Waters
(Milford, MA) coupled to an electrochemical detector (potential
maintained at 0.35 V; Coulochem model 5100A; ESA, Bedford, MA).
Standard calibration curves were prepared as peak area (µV ·
s/10
6) versus concentration of neurotransmitter
(ng/µl) and the concentrations of neurotransmitters and metabolites
in samples were then back-calculated. Retention times were distinct for
each compound analyzed. Chemicals, along with HPLC grade methyl alcohol
and water, were obtained from Sigma Chemical Co.
Data Analysis. Computer analysis of radioligand binding and uptake data were performed with Prism v2.0 (GraphPAD Software, San Diego, CA), using iterative curve-fitting techniques. A coefficient of determination was calculated for each set of data as an indicator of how well the data fit the function, similar to a correlational coefficient. Saturation and competition data were fit to one- or two-component models and evaluated for goodness-of-fit by Sheffé's F test. Bmax, Kd, and Ki were thus determined. Experiments involving multiple conditions, both cocaine dose and hours of treatment, were analyzed using a repeated-measures, two-way ANOVA model, followed by Tukey's multiple comparison tests. In those experiments involving comparisons between two paired wells, paired Student's t test was used. Experiments involving one treatment time with multiple treatments were analyzed using a one-way ANOVA model, followed by Dunnett's multiple comparison tests. For every experimental issue addressed, at least three independent experiments were performed (the degrees of freedom are noted below with the data for each experiment).
| |
Results |
|---|
|
|
|---|
Effects of Cocaine Treatment on [3H]WIN 35428 Binding
and [3H]Dopamine Uptake.
As seen in Fig.
1, relatively high doses of cocaine were
required to induce a change in hDAT binding. At cocaine doses of 10
5 or 10
6 M, there
were clear and statistically significant increases in [3H]WIN 35428 binding. The changes induced in
the dopamine transporter were not rapid and required at least 12 h
for increases in [3H]WIN 35428 binding to
become significant (see Fig. 2). Once
established, the [3H]WIN 35428 binding changes
persisted at similar levels for 48 h. Figure
3 demonstrates that the changes in
binding were paralleled by increases in dopamine uptake
Vmax. The increase seemed to occur at
an increased rate compared with the induced binding changes, reaching
statistical significance at 3 h. The increases in
Vmax were of a similar magnitude as
the [3H]WIN 35428 binding
Bmax increases. There were no changes
in affinity for inhibitor or substrate in either binding or uptake
experiments.
|
|
|
|
Effects of Other DAT Inhibitors Treatment on [3H]WIN 35428 Binding. To assess the specificity of the cocaine effect, hDAT-N2A cells were treated similarly for 24 h with two DAT inhibitors believed to have similar functional effects: methylphenidate and WIN35428. The doses used were near their Kd values for the DAT: 100 nM for methylphenidate and 10 nM for WIN 35428. Both drugs caused similar increases in [3H]WIN 35428 Bmax compared with vehicle-treated control cells, of 21 ± 4% (methylphenidate, n = 3 well plates each) or 26 ± 3% (n = 3 well plates each, WIN 35428).
Effects of Cocaine Treatment on Total DAT Concentrations, DAT mRNA,
and Subcellular Location.
A preliminary biotinylation experiment
found that 64% of hDAT was intracellular and 36% on the surface
basally in the hDAT-N2A cells [based on quantified relative optical
densities (RODs); see Fig. 5A]. Further
experiments conducted after 24 h of treatment with 1 µM cocaine,
determined that cocaine-induced increases in hDAT function did not
involve an increase in synthesis of DAT molecules. Western blots of the
DAT showed no increase in total DAT immunoreactivity after cocaine
exposure (1 µM for 24 h; see Fig. 5B), but surface hDAT, as
measured by biotinylation, was significantly increased (biotinylated
DAT IR 0.39 ± 0.03 ROD in vehicle-treated cells versus 0.50 ± 0.04 in cocaine-treated (t = 2.40, df = 7, p = 0.04). Consistent with these results suggesting that trafficking mechanisms were involved was a clear visual increase in DAT-immunoreactive labeling of the outer rim of cocaine-treated cells (as shown in Fig. 6). When
digitized and quantitated, this effect was found to be statistically
significant (see Fig. 7). Conversely, DAT
immunofluorescence was mildly decreased intracellularly. Control
experiments that involved treating hDAT-N2A cells with PMA (5 µm for
60 min) caused statistically significant increases in cytoplasmic and
large inclusion DAT immunofluorescence, with a trend noted toward
decreased outer membrane DAT-immunofluoresence. Figure
8 demonstrates the appearance of hDAT
immunofluorescence through the extent of a cocaine-treated cell with a
series of z-sections.
|
|
|
|
|
|
Possible Role of Phosphorylation.
As shown in Fig.
11, cells treated with cocaine (1 µM × 24 h, and demonstrating increased DAT function)
showed no change in their responsiveness to treatment with PMA, which
has been shown to cause internalization of DAT via protein kinase C
phosphorylation (Pristupa et al., 1998
).
|
Possible Involvement of Dopamine and Serotonin as Intracellular
Messengers.
Because it was possible that the effect of cocaine
depended on reversing the basal suppression of hDAT expression by low
levels of dopamine present in serum, further experiments incubating
hDAT-N2A cells with dopamine for 24 h in concentrations from
10
8 to 10
5 M were
performed. An inhibiting effect on [3H]WIN
35428 binding was found only at the highest concentration (see Table
1). There was no evidence of cell
toxicity, as measured by total protein, which was equivalent to
controls at all four concentrations of dopamine. The presence of
residual dopamine possibly contributed to the decrease in
[3H]WIN 35428 binding seen at
10
5 M, although dopamine concentrations were
probably much diluted. Incubation with the same concentration range of
serotonin found no diminishment in [3H]WIN
35428 Bmax or affinity, nor any change
in total protein levels. One other indicator that dopamine played no
role in cocaine-induced trafficking, hDAT-N2A neurons grown in
serum-free medium (which is dialyzed to remove any trace levels of
dopamine), demonstrated a similar pattern of cocaine-induced DAT
increases.
|
|
| |
Discussion |
|---|
|
|
|---|
The present experiments extend our earlier report in N2A cells
(Zhang et al., 1998
), and model features that have been discovered in
postmortem specimens from human cocaine users, including increased [3H]WIN 35428 binding (Little et al., 1993
,
1999
; Staley et al., 1994
), increased
[3H]dopamine uptake (Mash et al., 1997
),
without increases in DAT mRNA (Little et al., 1998
).
A number of independent measures demonstrated the presence of increased, functional DAT after cocaine treatment. This increase seemed restricted to the cell surface, based on biotinylation and confocal microscopic results. The lack of change in DAT mRNA or total protein levels, and the failure of cyclohexamide treatments that markedly inhibited protein synthesis to block the effects of cocaine, further indicate there was no change in total number of DAT molecules. Other control experiments indicate that the effect of cocaine was specific to the DAT because cocaine treatment caused no changes in [3H]leucine uptake or actin protein levels. The magnitude of the increases detected with the various measures were similar at 24 h, with a 37% increase recorded in dopamine Vmax, a 34% increase in [3H]WIN 35428 Bmax, a 35% increase in outer membranal labeling using confocal microscopy, and a 28% increase in biotinylated hDAT. The small differences probably reflect to some degree differences between measures in their selectivity for membrane-inserted hDAT versus internalized hDAT. Although the decrease in nonbiotinlylated DAT after cocaine treatment was not statistically significant on Western blots, this probably reflects the much larger intracellular volume and greater absolute amounts of intracellular DAT, compared with that of the plasma membrane, and would have been expected to demonstrate smaller percentage changes after cocaine treatment.
The present results can be compared with those reported by Saunders et
al. (2000)
using hDAT-FLAG expressed in human embryonic kidney 293-EM4
cells. These investigators found that 2 µM d-amphetamine increased internalization of surface DAT within 1 h on confocal microscopy and in whole-cell current recordings. We have also noted an
opposite effect of d-amphetamine on hDAT binding compared with (-)-cocaine (Little and Zhang, 1998
).
Compared with the results of Saunders et al. (2000)
, cocaine effects on
[3H]WIN 35428 binding were slower developing in
the present experiments, suggesting that detection of changes in
[3H]WIN 35428 binding may require a greater
relative shift in the distribution of DAT to the cell surface than
other measures, perhaps because of some limits to its selectivity for
plasma membrane versus intracellular DAT fractions. Consistent with
this explanation, cocaine- induced increases in
[3H]dopamine uptake were more rapid. In our
experiments, we emphasized [3H]WIN 35428 binding as our primary measure of (
)-cocaine effect because it
represents the DAT measure of most practical use in clinical studies.
It is possible that markedly distinct mechanisms are at play in the
processes noted here versus those caused by d-amphetamine as
described by Saunders et al (2000)
. However, cocaine-induced redistribution of DAT to the surface might involve similar pathways and
seem slower in hDAT-N2A cells than DAT internalization in d-amphetamine-treated EM4 cells simply because of relative
differences in basal state DAT distribution patterns for the two types
of cells. In contrast to hDAT-N2A cells, EM4 cells displayed very little internal DAT fluorescence basally. Thus, the kinetics of surface
versus intracellular distribution seem to favor a membrane locale in
EM4 cells, an ideal situation for measuring shifts toward intracellular
accumulation. In contrast, in the hDAT-N2A cells, which basally display
more intracellular hDAT, redistribution effects may take longer to
detect because of the more even distribution between the two compartments.
Daniels et al. (1999)
have recently described PMA-induced trafficking
of a green fluorescent protein-tagged DAT expressed in Madin-Darby
canine kidney cells. Similar to the cells used by Saunders et al.
(2000)
, these cells display little basal intracellular DAT
fluorescence, which markedly increases after PMA treatment. In
contrast, Melikian and Buckley (1999)
, using the same hDAT-pcDNA3 construct as presently described, transfected into a neuronal cell
PC12, reported that 63% of hDAT IR was intracellular in studies employing biotinylation and sucrose gradient ultracentrifugation. Together, these results suggest that tagged DAT may have a shorter half-life after internalization and increased lysosomal degradation rates compared with untagged DAT. Supporting this idea, Daniels and
Amara (1999)
found that 0.1 µM PMA treatment for 1 h caused extensive DAT-green fluorescent protein fluorescence colocalized with
AC-17 (anti-lysosomal glycoprotein antibody)-labeled vesicles and a
considerable loss of total DAT IR on Western blots. Conversely, Melikian and Buckley (1999)
, working with untagged DAT, found that 30 min of 1 µM PMA induced internalization of DAT IR that was
nearly all concentrated in the transferrin-labeled recycling compartment, not in the EEA1-labeled slow endosome compartment (which
is prelysosomal). Against the possibility that the antibodies used in
the current experiments labeled another protein in addition to DAT were
the control experiments with nontransfected N2A cells, which
demonstrated only background immunofluorescence.
Moderate doses of dopamine or serotonin did not effect the DAT. If an
inhibiting effect had existed, then the presently described cocaine
increases might have reflected a reversal of an intracellular dopamine
effect. Further indicating that dopamine was not involved in the
presently described trafficking phenomenon, hDAT-N2A neurons grown in
serum-free medium also demonstrated cocaine-induced up-regulation. In a
previous report, Saunders et al. (2000)
found that 100 µM dopamine
for 1 h increased DAT internalization in a manner similar to 2 µM d-amphetamine. These results seem consistent with the present findings, which found that high doses of dopamine decreased [3H]WIN 35428 binding, after a longer treatment period.
The quantification of immunofluorescence by confocal microscopy can be
confounded by a number of factors including inadequate matching of the
3D plane, differences in cell growth, and the fading of
immunofluorescence, among others (Nagelhus et al., 1996
). Although the
present experiments may not have eliminated all the variability caused
by these factors, the quantification of different treatment groups was
carefully balanced. The cocaine-induced increase in plasma membrane and
decrease in large inclusion-associated immunofluoresence were
consistent with the biotinylation results, which found increased cell
surface DAT, no increase in total DAT, and a trend toward decreased
intracellular DAT.
Previous experiments have alternatively used either sucrose/phosphate
buffer or Tris buffer (Madras et al., 1989
; Little et al., 1993
; 1998
),
with some evidence suggesting that a two-site model is more likely in
low sodium buffers, perhaps partly because of binding to filter paper
(Chen et al., 1997
). Although Tris decreases total DAT binding (Reith
et al., 1984
), the current experiments found that cocaine-induced
[3H]WIN 35428 binding site increases can be
detected in either TRIS or sucrose/phosphate buffer. In different
experiments, [3H]WIN 35428 binding displayed
Kd values ranging from 5 to 21 nM (see
Table 1), but Kd values were never
different in cocaine-treated cells compared with similarly plated
control cells, and were similar to the
Kd values detected in human brain
experiments (16.3 ± 4.3 nM, Little et al., 1999
). Dopamine uptake
affinity in the hDAT-N2A cells has varied in the 200 to 500 nM range in
our laboratory over a period of several years, and the range of
[3H]dopamine uptake
Km values reported in the current
experiments are somewhat lower than have been reported in other
DAT-expressing cells. However, in all the studies reported here,
control cells were grown and plated in equal numbers as treated cells,
for each saturation experiment, and no sign of cocaine effect on
Km or Kd values was found.
Although a comparison of dose concentrations and time scales between
cells in culture and living animals or humans is inexact, the present
results parallel animal experiments finding that relatively large
cumulative doses of cocaine (generally more than 200 mg/kg/rat) are
required to consistently cause DAT up-regulation (Alburges et al.,
1993
; Koff et al., 1994
; Wilson et al., 1994
; Hitri et al., 1996
;
Letchworth et al., 2000
). However, the 1 µM cocaine dose repeatedly
administered in the present study is within the range reported in blood
or brain from human cocaine users (generally 0.1 to 1 µM range,
Foltin and Fischman, 1991
; Isenschmid et al., 1992
; Lukas et al.,
1996
).
In summary, cocaine treatment of hDAT-N2A cells models features detected in postmortem striatal samples from human cocaine users and suggests a possible mechanism for the observed increases in [3H]WIN 35428 binding. Cocaine regulation of DAT trafficking in hDAT-N2A neurons did not require the mediation of dopamine, but it is possible that intact dopamine neurons incorporate mechanisms for adjusting DAT function based on dopamine levels. The present model system should prove useful in better understanding the complex relationship between alterations in DAT radioligand binding and DAT protein trafficking. Confusion about these phenomena probably contributes to the current conflicting interpretations of existing in vitro and in vivo radioligand experiments.
| |
Acknowledgments |
|---|
We gratefully acknowledge Patrick R. McFinton, G. H. KeikiLani Hewlett, Dr. Huda Akil, and Dr. Margaret Gnegy for their assistance.
| |
Footnotes |
|---|
Received May 15, 2001; Accepted November 6, 2001
This work was supported by National Institutes of Health award DA09491 (to K.Y.L.) and a Veterans' Affairs Merit Award (to K.Y.L.).
Karley Y. Little, M.D., Laboratory of Affective Neuropharmacology/116-A, Ann Arbor VAMC, 2215 Fuller Rd., Ann Arbor, MI 48105. E-mail: kylittle{at}umich.edu
| |
Abbreviations |
|---|
hDAT, human dopamine transporter; MAT, monoamine transporter; N2A, neuro2a murine neuroblastoma cells; FBS, fetal bovine serum; PAGE, polyacrylamide gel electrophoresis; TTBS, Tris-buffered saline/Tween 20; PBS, phosphate-buffered saline; CDP-Star, disodium 2-chloro-5-(4-methoxyspiro{1,2-dioxetane-3,2'-(5'-chloro)tricyclo [3.3.1.13,7]decan}-4-yl)-1-phenyl phosphate; HPLC, high-performance liquid chromatography; ANOVA, analysis of variance; ROD, relative optical density.
| |
References |
|---|
|
|
|---|
-(4-[125I]iodophenyl)tropane-2
-carboxylic acid isopropyl ester to the dopamine transporter.
J Neurochem
68:
1968-1981[Medline].
-Carbomethoxy-3
-(4-fluorophenyl) tropane.
Mol Pharmacol
36:
518-524[Abstract].This article has been cited by other articles:
![]() |
S. Tavoulari, L. R. Forrest, and G. Rudnick Fluoxetine (Prozac) Binding to Serotonin Transporter Is Modulated by Chloride and Conformational Changes J. Neurosci., July 29, 2009; 29(30): 9635 - 9643. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhu, C. F. Mactutus, D. R. Wallace, and R. M. Booze HIV-1 Tat Protein-Induced Rapid and Reversible Decrease in [3H]Dopamine Uptake: Dissociation of [3H]Dopamine Uptake and [3H]2{beta}-Carbomethoxy-3-{beta}-(4-fluorophenyl)tropane (WIN 35,428) Binding in Rat Striatal Synaptosomes J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 1071 - 1083. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Furman, R. Chen, B. Guptaroy, M. Zhang, R. W. Holz, and M. Gnegy Dopamine and Amphetamine Rapidly Increase Dopamine Transporter Trafficking to the Surface: Live-Cell Imaging Using Total Internal Reflection Fluorescence Microscopy J. Neurosci., March 11, 2009; 29(10): 3328 - 3336. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Yu, J. Becnel, M. Zerfaoui, R. Rohatgi, A. H. Boulares, and C. D. Nichols Serotonin 5-Hydroxytryptamine2A Receptor Activation Suppresses Tumor Necrosis Factor-{alpha}-Induced Inflammation with Extraordinary Potency J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 316 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lau, S. Horschitz, S. Berger, D. Bartsch, and P. Schloss Antidepressant-induced internalization of the serotonin transporter in serotonergic neurons FASEB J, June 1, 2008; 22(6): 1702 - 1714. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wei, J. M. Williams, C. Dipace, U. Sung, J. A. Javitch, A. Galli, and C. Saunders Dopamine Transporter Activity Mediates Amphetamine-Induced Inhibition of Akt through a Ca2+/Calmodulin-Dependent Kinase II-Dependent Mechanism Mol. Pharmacol., March 1, 2007; 71(3): 835 - 842. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Kahlig, B. J. Lute, Y. Wei, C. J. Loland, U. Gether, J. A. Javitch, and A. Galli Regulation of Dopamine Transporter Trafficking by Intracellular Amphetamine Mol. Pharmacol., August 1, 2006; 70(2): 542 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. G. Garcia, Y. Wei, J. A. Moron, R. Z. Lin, J. A. Javitch, and A. Galli Akt Is Essential for Insulin Modulation of Amphetamine-Induced Human Dopamine Transporter Cell-Surface Redistribution Mol. Pharmacol., July 1, 2005; 68(1): 102 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wang and M. W. Quick Trafficking of the Plasma Membrane {gamma}-Aminobutyric Acid Transporter GAT1: SIZE AND RATES OF AN ACUTELY RECYCLING POOL J. Biol. Chem., May 13, 2005; 280(19): 18703 - 18709. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Kahlig, J. A. Javitch, and A. Galli Amphetamine Regulation of Dopamine Transport: COMBINED MEASUREMENTS OF TRANSPORTER CURRENTS AND TRANSPORTER IMAGING SUPPORT THE ENDOCYTOSIS OF AN ACTIVE CARRIER J. Biol. Chem., March 5, 2004; 279(10): 8966 - 8975. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Middleton, W. A. Cass, and L. P. Dwoskin Nicotinic Receptor Modulation of Dopamine Transporter Function in Rat Striatum and Medial Prefrontal Cortex J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 367 - 377. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chi and M. E. A. Reith Substrate-Induced Trafficking of the Dopamine Transporter in Heterologously Expressing Cells and in Rat Striatal Synaptosomal Preparations J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 729 - 736. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Loder and H. E. Melikian The Dopamine Transporter Constitutively Internalizes and Recycles in a Protein Kinase C-regulated Manner in Stably Transfected PC12 Cell Lines J. Biol. Chem., June 6, 2003; 278(24): 22168 - 22174. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sabeti, G. A. Gerhardt, and N. R. Zahniser Individual Differences in Cocaine-Induced Locomotor Sensitization in Low and High Cocaine Locomotor-Responding Rats Are Associated with Differential Inhibition of Dopamine Clearance in Nucleus Accumbens J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 180 - 190. [Abstract] [Full Text] |
||||
![]() |
D. Milne Cocaine Appears to Damage Brain's Dopamine Neurons Psychiatr News, February 7, 2003; 38(3): 22 - 22. [Full Text] |
||||
![]() |
G. E. Torres, A. Carneiro, K. Seamans, C. Fiorentini, A. Sweeney, W.-D. Yao, and M. G. Caron Oligomerization and Trafficking of the Human Dopamine Transporter. MUTATIONAL ANALYSIS IDENTIFIES CRITICAL DOMAINS IMPORTANT FOR THE FUNCTIONAL EXPRESSION OF THE TRANSPORTER J. Biol. Chem., January 17, 2003; 278(4): 2731 - 2739. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Y. Little, D. M. Krolewski, L. Zhang, and B. J. Cassin Loss of Striatal Vesicular Monoamine Transporter Protein (VMAT2) in Human Cocaine Users Am J Psychiatry, January 1, 2003; 160(1): 47 - 55. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sabeti, G. A. Gerhardt, and N. R. Zahniser Acute Cocaine Differentially Alters Accumbens and Striatal Dopamine Clearance in Low and High Cocaine Locomotor Responders: Behavioral and Electrochemical Recordings in Freely Moving Rats J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1201 - 1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Maiya, K. J. Buck, R. A. Harris, and R. D. Mayfield Ethanol-sensitive Sites on the Human Dopamine Transporter J. Biol. Chem., August 16, 2002; 277(34): 30724 - 30729. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||